

Present ATC code	ATC classification - Proposal 1	New ATC code proposal	Notes
------------------	---------------------------------	-----------------------	-------

L04A IMMUNOSUPPRESSANTS

L04AA Selective immunosuppressants

L04AA03	antilymphocyte immunoglobulin (horse)	L04AA03	unchanged
L04AA04	antithymocyte immunoglobulin (rabbit)	L04AA04	unchanged
L04AA06	mycophenolic acid	L04AA06	unchanged
L04AA15	alefacept	L04AA15	unchanged
L04AA19	gusperimus	L04AA19	unchanged
L04AA22	abetimus	L04AA22	unchanged
L04AA24	abatacept	L04AA24	unchanged
L04AA28	belatacept	L04AA28	unchanged
L04AA32	apremilast	L04AA32	unchanged
L04AA40	cladribine	L04AA40	unchanged
L04AA41	imlifidase	L04AA41	unchanged
L04AA48	belumosudil	L04AA48	unchanged
L04AA54	pegcetacoplan	L04AA54	unchanged
L04AA58	etgartigimod alfa	L04AA58	unchanged

L04AB Tumor necrosis factor alpha (TNF- α) inhibitors

L04AB01	etanercept	L04AB01	unchanged
L04AB02	infliximab	L04AB02	unchanged
L04AB03	afelimomab	L04AB03	unchanged
L04AB04	adalimumab	L04AB04	unchanged
L04AB05	certolizumab pegol	L04AB05	unchanged
L04AB06	golimumab	L04AB06	unchanged
L04AB07	opinercept	L04AB07	unchanged

L04AC Interleukin inhibitors

L04AC01	daclizumab	L04AC01	unchanged
L04AC02	basiliximab	L04AC02	unchanged
L04AC03	anakinra	L04AC03	unchanged
L04AC04	rilonacept	L04AC04	unchanged
L04AC05	ustekinumab	L04AC05	unchanged
L04AC07	tocilizumab	L04AC07	unchanged
L04AC08	canakinumab	L04AC08	unchanged
L04AC09	briakinumab	L04AC09	unchanged
L04AC10	secukinumab	L04AC10	unchanged
L04AC11	siltuximab	L04AC11	unchanged
L04AC12	brodalumab	L04AC12	unchanged
L04AC13	ixekizumab	L04AC13	unchanged

L04AC14	sarilumab	L04AC14	unchanged
L04AC15	sirukumab	L04AC15	unchanged
L04AC16	guselkumab	L04AC16	unchanged
L04AC17	tildrakizumab	L04AC17	unchanged
L04AC18	risankizumab	L04AC18	unchanged
L04AC19	satralizumab	L04AC19	unchanged
L04AC20	netakimab	L04AC20	unchanged
L04AC21	bimekizumab	L04AC21	unchanged
L04AC22	spesolimab	L04AC22	unchanged

L04AD Calcineurin inhibitors

L04AD01	ciclosporin	L04AD01	unchanged
L04AD02	tacrolimus	L04AD02	unchanged
L04AD03	voclosporin	L04AD03	unchanged

L04AE Sphingosine 1-phosphate (S1P) receptor modulators

L04AA27	fingolimod	L04AE01	
L04AA38	ozanimod	L04AE02	
L04AA42	siponimod	L04AE03	
L04AA50	ponesimod	L04AE04	

L04AF Janus-associated kinase (JAK) inhibitors

L04AA29	tofacitinib	L04AF01	
L04AA37	baricitinib	L04AF02	
L04AA44	upadacitinib	L04AF03	
L04AA45	filgotinib	L04AF04	
L04AA46	itacitinib	L04AF05	
L04AA49	peficitinib	L04AF06	
L04AA56	deucravacitinib	L04AF07	

L04AG Monoclonal antibodies

1

L04AA02	muromonab-CD3	L04AG01	
L04AA21	efalizumab	L04AG02	
L04AA23	natalizumab	L04AG03	
L04AA25	eculizumab	L04AG04	
L04AA26	belimumab	L04AG05	
L04AA33	vedolizumab	L04AG06	
L04AA34	alemtuzumab	L04AG07	
L04AA35	begelomab	L04AG08	
L04AA36	ocrelizumab	L04AG09	
L04AA39	emapalumab	L04AG10	
L04AA43	ravulizumab	L04AG11	
L04AA47	inebilizumab	L04AG12	
L04AA51	anifrolumab	L04AG13	

L04AA52	ofatumumab	L04AG14	
L04AA53	teprotumumab	L04AG15	
L04AA55	sutimlimab	L04AG16	
L04AA57	ublituximab	L04AG17	
L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors			
L04AA10	sirolimus	L04AH01	
L04AA18	everolimus	L04AH02	
L04AI Dihydroorotate dehydrogenase (DHODH) inhibitors			
L04AA13	leflunomide	L04AI01	
L04AA31	teriflunomide	L04AI02	
L04AX Other immunosuppressants			
L04AX01	azathioprine	L04AX01	unchanged
L04AX02	thalidomide	L04AX02	unchanged
L04AX03	methotrexate	L04AX03	unchanged
L04AX04	lenalidomide	L04AX04	unchanged
L04AX05	pirfenidone	L04AX05	unchanged
L04AX06	pomalidomide	L04AX06	unchanged
L04AX07	dimethyl fumarate	L04AX07	unchanged
L04AX08	darvadstrocel	L04AX08	unchanged
L04AX09	diroximel fumarate	L04AX09	unchanged

Comments

1. Monoclonal antibodies acting as tumor necrosis factor alpha inhibitors are classified in L04AB - *Tumor necrosis factor alpha (TNF- α) inhibitors* . Monoclonal antibodies acting as interleukin inhibitors are classified in L04AC - *Interleukin inhibitors* . All other immunosuppressant monoclonal antibodies are classified here.

Present ATC code	ATC classification - Proposal 2	New ATC code proposal	Notes
L04A IMMUNOSUPPRESSANTS, EXCL. AGENTS FOR MULTIPLE SCLEROSIS AND TRANSPLANT REJECTION			1,2
L04AA Selective immunosuppressants			
L04AA13	leflunomide	L04AA13	unchanged
L04AA15	alefacept	L04AA15	unchanged
L04AA19	gusperimus	L04AA19	unchanged
L04AA22	abetimus	L04AA22	unchanged
L04AA24	abatacept	L04AA24	unchanged
L04AA32	apremilast	L04AA32	unchanged
L04AA54	pegcetacoplan	L04AA54	unchanged
L04AA58	efgartigimod alfa	L04AA58	unchanged
L04AB Tumor necrosis factor alpha (TNF-α) inhibitors			
L04AB01	etanercept	L04AB01	unchanged
L04AB02	infliximab	L04AB02	unchanged
L04AB03	afelimomab	L04AB03	unchanged
L04AB04	adalimumab	L04AB04	unchanged
L04AB05	certolizumab pegol	L04AB05	unchanged
L04AB06	golimumab	L04AB06	unchanged
L04AB07	opinercept	L04AB07	unchanged
L04AC Interleukin inhibitors			3
L04AC01	daclizumab	L04AC01	unchanged
L04AC03	anakinra	L04AC03	unchanged
L04AC04	rilonacept	L04AC04	unchanged
L04AC05	ustekinumab	L04AC05	unchanged
L04AC07	tocilizumab	L04AC07	unchanged
L04AC08	canakinumab	L04AC08	unchanged
L04AC09	briakinumab	L04AC09	unchanged
L04AC10	secukinumab	L04AC10	unchanged
L04AC11	siltuximab	L04AC11	unchanged
L04AC12	brodalumab	L04AC12	unchanged
L04AC13	ixekizumab	L04AC13	unchanged
L04AC14	sarilumab	L04AC14	unchanged
L04AC15	sirukumab	L04AC15	unchanged
L04AC16	guselkumab	L04AC16	unchanged
L04AC17	tildrakizumab	L04AC17	unchanged
L04AC18	risankizumab	L04AC18	unchanged
L04AC19	satralizumab	L04AC19	unchanged
L04AC20	netakimab	L04AC20	unchanged

L04AC21	bimekizumab	L04AC21	unchanged
L04AC22	spesolimab	L04AC22	unchanged
L04AD Calcineurin inhibitors			4
L04AD01	ciclosporin	L04AD01	unchanged
L04AD03	voclosporin	L04AD03	unchanged
L04AE Monoclonal antibodies			5
L04AA21	efalizumab	L04AE01	
L04AA25	eculizumab	L04AE02	
L04AA26	belimumab	L04AE03	
L04AA33	vedolizumab	L04AE04	
L04AA35	begelomab	L04AE05	
L04AA39	emapalumab	L04AE06	
L04AA43	ravulizumab	L04AE07	
L04AA47	inebilizumab	L04AE08	
L04AA51	anifrolumab	L04AE09	
L04AA53	teprotumumab	L04AE10	
L04AA55	sutimlimab	L04AE11	
L04AF Janus-associated kinase (JAK) inhibitors			6
L04AA29	tofacitinib	L04AF01	
L04AA37	baricitinib	L04AF02	
L04AA44	upadacitinib	L04AF03	
L04AA45	filgotinib	L04AF04	
L04AA49	peficitinib	L04AF05	
L04AA56	deucravacitinib	L04AF06	
L04AX Other immunosuppressants			
L04AX01	azathioprine	L04AX01	unchanged
L04AX02	thalidomide	L04AX02	unchanged
L04AX03	methotrexate	L04AX03	unchanged
L04AX04	lenalidomide	L04AX04	unchanged
L04AX05	pirfenidone	L04AX05	unchanged
L04AX06	pomalidomide	L04AX06	unchanged
L04AX08	darvadstrocel	L04AX08	unchanged
L04B IMMUNOSUPPRESSANTS FOR TRANSPLANT REJECTION			7
L04BA Monoclonal antibodies for transplant rejection			8
L04AA02	muromonab-CD3	L04BA01	
L04AC02	basiliximab	L04BA02	

L04BB Mammalian target of rapamycin (mTOR) kinase inhibitors		
L04AA10	sirolimus	L04BB01
L04AA18	everolimus	L04BB02

L04BX Other immunosuppressants for transplant rejection		
L04AA03	antilymphocyte immunoglobulin (horse)	L04BX01
L04AA04	antithymocyte immunoglobulin (rabbit)	L04BX02
L04AA06	mycophenolic acid	L04BX03
L04AD02	tacrolimus	L04BX04
L04AA28	belatacept	L04BX05
L04AA41	imlifidase	L04BX06
L04AA46	itacitinib	L04BX07
L04AA48	belumosudil	L04BX08

L04C IMMUNOSUPPRESSANTS FOR MULTIPLE SCLEROSIS		9
---	--	---

L04CA Monoclonal antibodies for multiple sclerosis		
L04AA23	natalizumab	L04CA01
L04AA34	alemtuzumab	L04CA02
L04AA36	ocrelizumab	L04CA03
L04AA52	ofatumumab	L04CA04
L04AA57	ublituximab	L04CA05

L04CB Sphingosine 1-phosphate (S1P) receptor modulators		
L04AA27	fingolimod	L04CB01
L04AA38	ozanimod	L04CB02
L04AA42	siponimod	L04CB03
L04AA50	ponesimod	L04CB04

L04CX Other immunosuppressants for multiple sclerosis		
L04AA31	teriflunomide	L04CX01
L04AX07	dimethyl fumarate	L04CX02
L04AA40	cladribine	L04CX03
L04AX09	diroximel fumarate	L04CX04

Comments

1. This group includes immunosuppressants, excluding agents for transplant rejection and multiple sclerosis.
2. Ozanimod and cladribine are classified in L04C - *Immunosuppressants for multiple sclerosis* .

3. Basiliximab is classified in L04BA - *Monoclonal antibodies for transplant rejection* .
 4. Tacrolimus is classified in L04BX - *Other immunosuppressants for transplant rejection* .
 5. Monoclonal antibodies acting as tumor necrosis factor alpha inhibitors are classified in L04AB - *Tumor necrosis factor alpha (TNF- α) inhibitors* . Monoclonal antibodies acting as interleukin inhibitors are classified in L04AC - *Interleukin inhibitors* . All other immunosuppressant monoclonal antibodies, excluding agents for transplant rejection and multiple sclerosis, are classified here.
 6. Itacitinib is classified in L04BX - *Other immunosuppressants for transplant rejection* .
 7. Daclizumab, ciclosporin, begelomab, azathioprine, and thalidomide are classified in L04A - *Immunosuppressants, excl. agents for multiple sclerosis and transplant rejection*.
 8. Beigelomab is classified in L04AE - *Monoclonal antibodies* .
 9. Daclizumab and azathioprine are classified in L04A - *Immunosuppressants, excl. agents for multiple sclerosis and transplant rejection* .
-